Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atea Pharmaceuticals (AVIR) Current Assets (2019 - 2026)

Atea Pharmaceuticals' Current Assets history spans 8 years, with the latest figure at $263.2 million for Q1 2026.

  • Quarterly Current Assets fell 39.31% to $263.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $263.2 million through Mar 2026, down 39.31% year-over-year, with the annual reading at $311.0 million for FY2025, 32.74% down from the prior year.
  • Current Assets came in at $263.2 million for Q1 2026, down from $311.0 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $713.2 million in Q1 2022 to a low of $263.2 million in Q1 2026.
  • The 5-year median for Current Assets is $548.8 million (2024), against an average of $525.1 million.
  • Year-over-year, Current Assets fell 9.95% in 2023 and then crashed 39.31% in 2026.
  • Atea Pharmaceuticals' Current Assets stood at $660.9 million in 2022, then decreased by 10.66% to $590.5 million in 2023, then fell by 21.7% to $462.4 million in 2024, then crashed by 32.74% to $311.0 million in 2025, then fell by 15.37% to $263.2 million in 2026.
  • Per Business Quant, the three most recent readings for AVIR's Current Assets are $263.2 million (Q1 2026), $311.0 million (Q4 2025), and $336.1 million (Q3 2025).